Technical Analysis for BYSI - BeyondSpring, Inc.

Grade Last Price % Change Price Change
grade F 17.2 0.53% 0.09
BYSI closed up 0.53 percent on Tuesday, March 19, 2019, on 63 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Apr 2

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical BYSI trend table...

Date Alert Name Type % Chg
Mar 19 Inside Day Range Contraction 0.00%
Mar 19 Oversold Stochastic Weakness 0.00%
Mar 18 New 52 Week Closing Low Bearish 0.53%
Mar 18 Lower Bollinger Band Touch Weakness 0.53%
Mar 18 Oversold Stochastic Weakness 0.53%
Mar 15 180 Bearish Setup Bearish Swing Setup -3.37%
Mar 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.37%
Mar 15 Narrow Range Bar Range Contraction -3.37%
Mar 15 Up 3 Days in a Row Strength -3.37%
Mar 15 Oversold Stochastic Weakness -3.37%

Older signals for BYSI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Chemistry Biopharmaceutical Cancer Clinical Medicine Chemotherapy Cancer Treatments Organic Chemistry Antineoplastic Drugs Cancer Therapies Docetaxel Advanced Non Small Cell Lung Cancer Buparlisib Imidazoles Neutropenia
Is BYSI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.3
52 Week Low 16.15
Average Volume 3,188
200-Day Moving Average 22.1364
50-Day Moving Average 18.263
20-Day Moving Average 18.0425
10-Day Moving Average 17.7215
Average True Range 0.7799
ADX 31.63
+DI 27.6362
-DI 19.2948
Chandelier Exit (Long, 3 ATRs ) 17.4303
Chandelier Exit (Short, 3 ATRs ) 19.2897
Upper Bollinger Band 19.2132
Lower Bollinger Band 16.8718
Percent B (%b) 0.14
BandWidth 12.977137
MACD Line -0.2837
MACD Signal Line -0.2053
MACD Histogram -0.0784
Fundamentals Value
Market Cap 392.92 Million
Num Shares 22.8 Million
EPS -3.71
Price-to-Earnings (P/E) Ratio -4.64
Price-to-Sales 0.00
Price-to-Book 16.76
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.89
Resistance 3 (R3) 17.97 17.81 17.78
Resistance 2 (R2) 17.81 17.64 17.78 17.74
Resistance 1 (R1) 17.51 17.53 17.43 17.43 17.70
Pivot Point 17.35 17.35 17.32 17.32 17.35
Support 1 (S1) 17.05 17.18 16.97 16.97 16.70
Support 2 (S2) 16.89 17.07 16.86 16.66
Support 3 (S3) 16.59 16.89 16.63
Support 4 (S4) 16.51